LivaNova
Company · London, United Kingdom
Global medtech company known for vagus nerve stimulation (VNS) therapy for epilepsy and treatment-resistant depression.
In the news
NeuromodulationResearch
Three-year CORE-VNS results show seizure reductions growing over time with LivaNova's VNS Therapy
In 531 people with drug-resistant epilepsy across 16 countries, median seizure frequency fell 76% after three years of vagus nerve stimulation, according to an observational study in Neuromodulation.
RegulationNeuromodulation
FDA approves LivaNova's aura6000 nerve stimulator for obstructive sleep apnea
The six-electrode hypoglossal nerve system activates airway muscles; 65% of patients responded at 12 months in the OSPREY trial.